Home・Lista de Ações・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Abrir

SetorSaúde

14.93 2.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.47

Máximo

14.8

Indicadores-chave
By Trading Economics
Rendimento	-176M 34M
Vendas	591K 78M
P/E Médio do Setor	7.112 64.641
EPS	0.25
Margem de lucro	44.212
Funcionários	128
EBITDA	2.7M 50M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+7.55% upside

Dividendos
By Acuity
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-92M 2B
Abertura anterior	12.46
Fecho anterior	14.93

Sentimento de Notícias

By Acuity

50%

151 / 340 Ranking em Healthcare

Aurinia Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 de ago. de 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 de jul. de 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 de jul. de 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 de jul. de 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 de jul. de 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 de jul. de 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 de jul. de 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 de jul. de 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 de jul. de 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 de jul. de 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Comparação entre Pares

Variação de preço

Aurinia Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

7.55% parte superior

Previsão para 12 meses

Média 15.67 USD 7.55%

Máximo 17 USD

Mínimo 15 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Aurinia Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para Aurinia Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

151 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.